2 May 2025 ACB News Sydney ：ImpediMed Limited (ASX: IPD) has reported record financial results for Q3 FY25, with revenue reaching A$3.4 million (+28% YoY), cash receipts at A$4.1 million, and ARR rising to A$13.7 million (+27% YoY). Total Contracted Value (TCV) hit A$4.9 million, up 53% from the previous quarter.
The company signed key renewals across U.S. NCCN centers and IDNs, achieving a 19% average uplift in pricing. Over 500 new sales leads were identified, with commercial deployments advancing across 28 IDNs. The SOZO® Pro device is undergoing clinical validation in heart failure and other indications.
To mitigate supply chain risks, ImpediMed will make a A$1.2 million payment in Q4 to secure critical components. FY25 operating costs are forecast to be 10% lower than FY24.
Shares rebounded last week after retesting the A$0.03 level, a key low first established in 2020, and reached an intraday high of A$0.042 on rising trading volume.
Key watchpoints include recurring revenue momentum, U.S. market execution, and progress in new clinical indications that could support a future re-rating.
Disclaimer
The information provided on this website is for general informational purposes only and does not constitute financial or investment advice. While every effort is made to ensure accuracy, we do not guarantee the completeness, reliability, or timeliness of any content. Investment involves risk. Always seek independent, professional advice before making any financial decisions.
